Linno Pharmaceuticals

Leading Innovation in Medical Sciences

Linno is dedicated to develop cutting-edge enabling technologies and novel therapeutic products to address major challenges in management of chronic human diseases. With proprietary Nano Brain-pass technology which enables blood-brain barrier-penetrating drug delivery for multiple forms of moieties, and next-generation pathway-selective complement inhibitors, Linno is working with partners to develop first- or best-of-class therapeutics, including orphan drugs for rare and devastating diseases.

About LINNO
领诺医药
Shape

Mission

Dedicated to R&D of novel therapeutics

Leveraging the proprietary technologies, Linno is working with partners to develop the first- or best-in-class therapeutics, including orphan drugs for rare and devastating diseases that have no available treatment exist yet.

Learn More

Committed to address the unmet medical needs

With Blood-brain barrier-penetrating technology and the next-generation pathway-selective complement inhibitors, we are delivering more effective, safe and affordable treatment to treat diseases driven by complement overactivation.

Learn More

Passionate to biopharmaceutical innovation

Leading innovation in scientific breakthrough, technology evolution, business exploration, as well as professional career development.

Learn More
+
Founded In the “PharmValley” of Zhangjiang, Shanghai
+
Dedicated scientists from concept generation to proof-of-concept
+
Core PCT Patents covering proprietary technologies and associated products
+
First- or best-in-class Pipeline products

Contact Linno

Let’s start the journey of caring, passion, joy, and reward.

Join us
Business collaboration
Investors

Request form

News

Thumb

Linno was certified as 'Key Institution' by the Zhangjiang Science Park

Such designation symbolizes a recognition of Linno’s innovative breakthrough in BBB-penetration technology and the next-generation pathway-selective complement inhibitors. With this designation, Linno would be qualified for support of “Talent recruitment”

18
2023-12

FDA granted a novel recombinant enzyme from Linno with “Orphan Drug Designation” (ODD) status for treatment of metachromatic leukodystrophy (MLD)

FDA granted a novel recombinant enzyme from Linno with “Orphan Drug Designation” (ODD) status for treatment of metachromatic leukodystrophy (MLD), a devastating inherited genetic disease that causes unmatured death of the affected pediatric patients.

04
2022-11

Linno hosted R&D Day to celebrate its 3rd anniversary

In the afternoon of November 4, 2022, at the newly opened Zhangjiang Science Hall, a new landmark in Pudong, Shanghai, Linno Pharmaceuticals Inc. (Linno) hosted R&D day to celebrate its 3rd anniversary, with guest speakers and representatives from lea

18
2022-07

Linno completed Pre-A fundraising, focusing on enabling technology of blood-brain barrier penetration and the next-generation pathway-selective complement inhibitors

Linno Pharmaceuticals Inc. (Linno) today announced the completion of the Pre-A fundraising led by Puhua Capital and ZJ LEADING VC.

Join us

  • Competitive compensation
  • Stock option
  • Healthcare Plan
  • Merit Award
  • Full benefits of social security
  • Personalized career development guidance and opportunities
Careers